Actively Recruiting
Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer
Led by Tang-Du Hospital · Updated on 2026-01-20
10
Participants Needed
1
Research Sites
315 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective,single-arm,Phase II clinical study to designed to evaluate the efficancy and safety of nimotuzumab Combined with Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer
CONDITIONS
Official Title
Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 80 years old inclusive
- Diagnosed with resectable locally advanced tonsillar squamous cell carcinoma confirmed by pathology and MRI
- At least one measurable lesion by RECIST Version 1.1
- Male participants agree to comply with contraception or abstinence during and up to 180 days after chemotherapy
- Female participants are not pregnant or breastfeeding and agree to use effective contraception or abstain during and up to 210 days after chemotherapy
- ECOG Performance Status 0-2 within 3 days before first treatment
- Evidence of extranodal extension in lymph nodes confirmed by MRI, CT, or pathology
- Voluntarily sign informed consent
- Expected survival of at least 6 months
- Adequate organ function based on blood counts, kidney, liver, and coagulation tests
- Good compliance and willingness to cooperate with follow-up
You will not qualify if you...
- Prior systemic therapy for advanced or unresectable tonsillar cancer except permitted neoadjuvant/adjuvant therapy completed at least 6 months prior
- Active autoimmune disease requiring systemic therapy within past 2 years
- Major surgery with inadequate recovery before study treatment
- Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, or EGFR-targeted agents
- Anti-tumor therapy or investigational drugs within 4 weeks before enrollment
- Unresolved adverse events from prior cancer therapy greater than Grade 1
- Radiotherapy within 2 weeks before study treatment without full recovery
- Live vaccines within 30 days before first study drug dose
- Participation in another investigational drug/device study within 4 weeks before first dose
- Immunodeficiency or recent systemic corticosteroid or immunosuppressive therapy
- History of invasive malignancy requiring treatment within past 3 years except certain skin and in situ cancers
- Severe hypersensitivity to study drugs or their components
- History or current pneumonitis requiring corticosteroids
- Active infection requiring systemic therapy
- Known HIV infection or active tuberculosis
- Severe uncontrolled concurrent diseases
- Major surgery within 30 days prior or planned during study
- CNS metastases or carcinomatous meningitis
- Psychiatric illness or substance abuse interfering with compliance
- History of allogeneic tissue or organ transplant
- Unwillingness or inability to consent or participate in study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tangdu Hospital, Air Force Medical University, Xi'an 710038, Shaanxi Province, China
Shanxi, Province, China
Actively Recruiting
Research Team
Z
Zhao DaQing
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here